{{Rsnum
|rsid=339097
|Gene=CALU
|Chromosome=7
|position=128759170
|Orientation=minus
|GMAF=0.04545
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CALU
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.0 | 2.2 | 97.8
| JPT | 0.0 | 0.9 | 99.1
| YRI | 2.7 | 30.6 | 66.7
| ASW | 0.0 | 28.1 | 71.9
| CHB | 0.0 | 2.2 | 97.8
| CHD | 0.9 | 0.9 | 98.2
| GIH | 0.0 | 0.0 | 0.0
| LWK | 2.7 | 28.2 | 69.1
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.6 | 17.9 | 81.4
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[http://web.me.com/russbaltman/Site/PharmGKBlog/Entries/2010/4/5_CALU_variants_and_high_warfarin_dose.html PharmGKB] indicates that this SNP is relevant to [[Warfarin]] dosing. rs339097(G) is associated with 14.5% higher therapeutic warfarin dose in African Americans. This variant is also more common in African Americans with minor allele frequencies of 11–14% , but only 0.2% in Caucasians.

{{PharmGKB
|RSID=rs339097
|Name_s=
|Gene_s=CALU
|Feature=
|Evidence=PubMed ID:20200517
|Annotation=Risk or phenotype-associated allele: G allele was associated with higher required warfarin dose. Phenotype: The G allele of this SNP was associated with a 14.5% (SD +/- 7%) higher therapeutic warfarin dose in African Americans. Study size/population/ethnicity: Discovery cohort was 108 outliers(53 patients in the low dose group and 55 in the high dose group) selected from patients who attended an outpatient anticoagulation clinic in St. Louis, Missouri. First replication cohort: 496 patients of mixed ethnicity who were patients at Washington U. Medical Center. Second replication cohort: 194 African-American patients from U. of Illinois, Chicago. Significance metric(s): First replication cohort: P = 0.03; Second replication cohort: one-sided P = 0.03. Type of association: CO; GN; PK
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291644
}}

{{PMID|21228733|OA=1
}} Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs339097
|overall_frequency_n=11
|overall_frequency_d=128
|overall_frequency=0.0859375
|n_genomes=11
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22676711
|Title=Pharmacogenomics of warfarin in populations of African descent.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}